Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
87.68
+0.05 (0.06%)
At close: Jun 26, 2026, 4:00 PM EDT
85.93
-1.75 (-2.00%)
After-hours: Jun 26, 2026, 6:49 PM EDT
Monopar Therapeutics Employees
Monopar Therapeutics had 22 employees as of December 31, 2025. The number of employees increased by 6 or 37.50% compared to the previous year.
Employees
22
Change (1Y)
6
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$681,135
Market Cap
587.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| 4D Molecular Therapeutics | 196 |
| CorMedix | 191 |
| Prime Medicine | 146 |
| BridgeBio Oncology Therapeutics | 106 |
| Tectonic Therapeutic | 60 |
| Altimmune | 57 |
MNPR News
- 1 day ago - Monopar Therapeutics announces new FoCus trial analyses - TheFly
- 1 day ago - Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - GlobeNewsWire
- 5 days ago - Monopar Therapeutics management to meet virtually with Piper Sandler - TheFly
- 23 days ago - Monopar Therapeutics Slides: Corporate presentation - Filings
- 26 days ago - Monopar Therapeutics presents ALXN1840-WD-205 data at EASL - TheFly
- 26 days ago - Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 - GlobeNewsWire
- 5 weeks ago - Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - GlobeNewsWire
- 6 weeks ago - Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire